1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Melanoma: KOL Insight 2016

Melanoma: KOL Insight 2016

  • November 2016
  • ID: 4833575
  • Format: PDF
  • By Firstword Pharma


Table of Contents


New combinations emerging as immunotherapies become the backbone therapy

Immunotherapies have become the go-to treatment for malignant melanoma, and with good reason. Not only are they proving to be the most effective single agents, they’re shaping up to be the backbone for a host of new combination therapies.

Learn what an immunotherapy-centric treatment algorithm means for patients and drug manufacturers in KOL Insight: Malignant Melanoma.
Twelve North American and European KOLs’ answer key questions about 9 marketed melanoma treatments and 5 currently in the pipeline.

You’ll find out which immunotherapies are most effective, and hear how they’re likely to be combined with existing and pipeline BRAF/MEK inhibitors, vaccines and immunostimulants, and other small-molecule therapies. You’ll also get insight into the key clinical trials that are shaping the market.

“The response rate is something like 10 percent for the single [Yervoy], but the combo [Yervoy+Opdivo] is closer to 50 and 60 percent. Single agent PD-1s [Keytruda and Opdivo] are in the 40s” US Key Opinion Leader

- Yervoy (ipilimumab; Bristol-Myers Squibb)
- Keytruda (pembrolizumab; Merck & Co.)
- Opdivo (nivolumab; Bristol-Myers Squibb)
- Zelboraf (vemurafenib; Roche)/Cotellic (cobimetinib; Roche)
- Mekinist (trametinib; GlaxoSmithKline)/Tafinlar (dabrafenib; GlaxoSmithKline)

- Igor Puzanov, MD, MSCI, FACP. Professor, Department of Medicine, Roswell Park Cancer Institute, Buffalo NY.
- Jean-Jacques Grob, MD. Head of the Dermatology and Skin Cancer Department, Timone APHM Hospital and Aix-Marseille University, Marseille, France.
- Philip A. Friedlander MD, PhD. Assistant Professor, Department of Dermatology, Mount Sinai School of Medicine, NY, USA.
- Reinhard Dummer, MD. Professor, Vice-Chairman, Department of Dermatology University Hospital of Zürich, Switzerland.
- Roger S. Lo, MD, PhD. Assistant Professor, Medicine and Molecular & Medical Pharmacology, Department of Medicine at UCLA, CA, USA.

Top Takeaways
- Immunotherapies are the new backbone: Not only have they emerged as the most effective monotherapies for melanoma patients, KOLs say they’ll soon be the backbone for most combinations as well. Which ones will see the most widespread uptake?
- The battle for top immunotherapy is on: Will Merck’s Keytruda or BMS’ Opdivo become physicians’ first choice. KOLs are unsure, but point to a variety of factors that will drive each agent’s uptake and use in combination therapies.
- Yervoy monotherapy down but not out: Even though immunotherapy combinations are fast becoming physicians’ first choice, KOLs note that Yervoy monotherapy won’t go away altogether. What kind of use will it continue to see?
- Bye bye, BRAF/MEK monotherapy: KOLs rarely use single agents to treat BRAF patients. Which of the two major combination regimens do they favour?
- Is there room for a new BRAF/MEK combination? A new encorafenib/binimetinib combination is on the way. How do KOLs expect it to fare against Roche’s Zelboraf /Cotellic and GSK’s Mekinist/Tafinlar?
- Finding a future for Imlygic: Seen as a niche product by most KOLs, Amgen’s Imlygic has the most potential in combination. Which agents are the most likely partners for combination use? In which setting do KOLs still see a role for Imlygic monotherapy?
- Little enthusiasm for other vaccines and immunostimulants: Do KOLs see potential for vaccines/immunostimulants other than Imlygic? What prospects do they see for the vaccine approach in general?
- Triple threat: As the trend towards more combination therapies intensifies, KOLs expect a BRAF/MEK/PD-1 triplet combination to emerge. What will determine whether such a combination finds a place in the treatment algorithm?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Bronchopulmonary Dysplasia - Pipeline Review, H2 2019

Bronchopulmonary Dysplasia - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Bronchopulmonary Dysplasia - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Bronchopulmonary Dysplasia - Pipeline Review, H2 2019, provides an overview of ...

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H2 2019

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Neuromyelitis Optica - Pipeline Review, H2 2019, provides an overview ...

Anthrax - Pipeline Review, H2 2019

Anthrax - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Anthrax - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Anthrax - Pipeline Review, H2 2019, provides an overview of the Anthrax (Infectious Disease) pipeline ...


Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on